Review Papers Against Their Own Results

Concise critical takeaway

The authors performed a pan-tissue analysis of ~17,000 GTEx RNAseq samples and report that age has a larger effect than sex on global transcriptome variation, but alternative splicing shows stronger sex-dimorphism than gene expression; male-biased age-associated splicing events associate more with Alzheimer disease, while female-biased splicing is linked to estrogen regulated splicing factors (ESR1, SRSF1, SRSF7). This conclusion is supported by multi-dataset integration (GTEx, ROSMAP, GEO) and breakpoint/ARIMA time-series analyses, but it is limited by bulk tissue data, variable sample sparsity, and the use of cancer-cell derived SF perturbation data for regulatory inference Pan-tissue transcriptome analysis paper

Paper review and critical analysis: Pan-tissue transcriptome analysis reveals sex-dimorphic human aging

Summary of what the paper claims (evidence-linked)

• Data scope and primary claim: The study analyzes ~17,000 RNA-seq samples from GTEx and related public datasets to quantify sex, age, and age-by-sex effects across 54 tissues, concluding that age explains more global transcriptome variance than sex but that alternative splicing (AS) shows stronger sex-dimorphism than gene expression (GE) Pan-tissue transcriptome analysis paper
• Mechanistic link to sex hormones: Female-specific splicing factor expression (SRSF1, SRSF7 etc.) appears estrogen/ESR1 responsive via ChIP-Atlas and cell experiments; male AMGs are enriched for immune/macrophage processes and linked to AR binding Hormone regulation of AMGs and SFs
• Disease link: Male-biased age-associated AS events (sBASEs) show stronger overlap/correlation with AD-associated splicing changes (ROSMAP confirmation); sex-stratified random-forest models using sBASEs predicted AD status better in males than females (examples: SLC43A2 exon10, FAM107A exons3/4) sBASEs and AD association

Major strengths (what the paper does well)

1. Scale and scope: Extensive pan-tissue resource (GTEx v8 ~16,200 samples across 54 tissues) gives statistical power to detect tissue-specific as well as global patterns and to compare GE vs AS at isoform resolution Data scope and GTEx usage
2. Multi-layer analyses: Combines GE, AS (PSI), ARIMA time-series, breakpoint analysis, regulator (SF) networks, ChIP and perturbation data—this triangulation increases confidence in mechanistic inferences.
3. Disease validation: Uses ROSMAP and GEO AD datasets to test relevance to Alzheimer's disease, not just descriptive aging signatures.

Principal limitations and critical caveats

• Bulk tissue confounding by cellular composition: GTEx is bulk RNA-seq and many reported GE/AS changes could reflect shifts in cell proportions (e.g., immune infiltration, glial shifts) rather than cell-intrinsic regulation; authors acknowledge this and note the limitation explicitly Bulk tissue limitation
• Use of cancer-cell derived SF perturbation and eCLIP data as scaffolds: The SF-RNA regulatory network used shRNA/eCLIP data from proliferative cancer cell lines (HepG2, K562) which may differ from post-mitotic brain cells; cross-cell-type extrapolation can introduce false regulatory edges. The authors attempt to mitigate this by intersecting with tissue-specific correlations but the approach remains indirect SF network caveat
• Hormone measurement/menopause timing not directly available: The ESR1/AR hormone arguments are plausible and supported by ChIP/perturbation datasets, but the GTEx donors lack longitudinal hormone measurements and timing of menopause—this weakens causal claims linking breakpoint ages to circulating hormone decline.
• Heterogeneous sample sizes across tissues and brain-region aggregation: Some tissues have small N and are excluded; brain regions were aggregated into 4 functional groups to gain power which may obscure region-specific effects.
• Predictive models have instability: Authors note high variation across training/testing due to limited AD sample sizes (GSE174367, ROSMAP matching); therefore AD prediction claims should be considered preliminary and require larger cohorts AD model caution

Technical and statistical appraisal

Quantification and pipelines

• ASE/GE quantification: GE quantified as TPM and AS as PSI using Paean; missing PSI imputed by kNN—reasonable but imputation may bias low-coverage events.
• Confounder control: Surrogate variables and permutation-based pcSVR for global variation and empirical p-values adds rigor, but disentangling batch effects that co-vary with sex/age remains intrinsically hard and authors preserved confounders in differential analysis to avoid over-correction Confounder handling
• Time-series modeling and breakpoints: ARIMA + LOESS + multi-window breakpoint pipeline is sensible; reproducibility would be helped by sharing parameterized code/mock notebooks (authors link to relevant repo family) ARIMA and breakpoint analysis

Biological interpretation and plausibility

• Sex hormones as regulators: The temporal alignment of transcriptomic breakpoints with known declines in testosterone (men, ~35–40) and estrogen (women, ~50) is biologically plausible, and their ChIP-Atlas + ESR1 perturbation evidence strengthens the case for hormone-mediated control of SF expression and downstream AS changes Hormone timing and ESR1 evidence
• Immune/mitochondrial sex differences plausibly map to known biology: Male-specific AMGs enriched in myeloid/macrophage processes and female AMGs enriched in mitochondrial respiratory processes align with literature describing sex differences in immune aging and mitochondria-driven longevity signals (separate reviews; authors cite supporting literature) AMG functional enrichment

Reproducibility and data availability

• Data availability: Authors point to dbGaP phs000424.v8.p2 (GTEx), GEO accessions (GSE174367 etc.), ROSMAP accession syn8540863; code links to previous repo family are referenced—this supports reproducibility if access permissions are obtained Data and accessions
• Reproducibility rating: methods are described in detail and public datasets are specified, but some steps (imputation choices, SV selection, ARIMA params) need explicit code/notebooks for perfect reproducibility; authors provide some pipelines but full replication will require computational resources and dbGaP access.

What would falsify the main claims?

1. Single-cell RNA-seq across many tissues showing that the sex-dimorphic AS patterns disappear after accounting for cell-type composition would argue the effects are composition-driven not intrinsic.
2. Large independent cohorts (e.g., multi-cohort brain AD datasets) failing to replicate the male bias in age-associated AS–AD overlap would weaken the disease link.
3. Direct hormone measurements across GTEx donors showing no temporal correlation between hormone decline and detected transcriptomic breakpoints would undercut the ESR1/AR timing argument.

Concrete suggestions to improve the work

• Integrate single-cell or nucleus RNA-seq deconvolution (e.g., Cell-type deconvolution with MuSiC, Bisque, CIBERSORTx) or use matched snRNA-seq atlases to partition cell-type versus cell-intrinsic AS/GE effects.
• Where possible, replicate SF regulatory networks using primary human cell perturbations (brain-derived glia/neuron cultures or iPSC-derived cell types) rather than cancer lines.
• Include donor hormone metadata when available, or use serum biomarker proxies to better link transcriptome breakpoints to endocrine changes.
• Make full analysis notebooks and parameter files available (ARIMA, LOESS bandwidths, kNN imputation settings) to maximize reproducibility.

Practical value and next steps for the field

This paper provides a valuable pan-tissue reference for sex-by-age transcriptomic variation and highlights isoform-level regulation as a crucial but under-exploited layer. Follow-up steps include single-cell validation, targeted mechanistic testing of ESR1->SRSF axis in brain-relevant glia/oligodendrocytes, and larger sex-stratified cohorts for AD splicing biomarkers.

Helpful bespoke resources and actions

Selected precise citation (primary)

Pan-tissue transcriptome analysis paper